; (B) management of information, and the acquisition, maintenance, and repair of computer resources; (C) leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; and (D) collecting fees under section 744L–1 and accounting for resources allocated for monograph drug activities. (4) The term firm establishment identifier is the unique number automatically generated by the Field Accomplishments and Compliance Tracking System of the Food and Drug Administration. (5) The term monograph drug shall have the meaning given the term under section 505G. (6) The term monograph drug activities means activities of the Secretary associated with monograph drug products and inspection of facilities associated with such products, including— (A) the activities necessary for review and evaluation of monograph drugs and monograph drug order requests, including— (i) orders proposing or finalizing applicable requirements of use for monograph drugs products; (ii) orders affecting status regarding general recognition of safety and effectiveness of a monograph drug ingredient or combination of ingredients under specified requirements of use; (iii) all monograph drug development and review activities, including intra-agency collaboration; (iv) regulation and policy development activities related to monograph drugs; (v) development of product standards for products subject to review and evaluation; (vi) meetings regarding monograph drug activities; (vii) review of labeling prior to issuance of orders related to monograph drugs or conditions of use; and (viii) regulatory science activities related to monograph drugs; (B) inspections related to monograph drugs; (C) monitoring of clinical and other research conducted in connection with monograph drugs